WebNov 12, 2024 · Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal ®, Cholbam ®, Thiola ® and Thiola EC ®. Retrophin.com. … WebTHIOLA® helps prevent cystine kidney stone formation in patients who are resistant to changes in diet and high fluid intake by keeping their cystine levels below the line of solubility. ... You may report negative side effects to Travere Therapeutics Medical Information at 1-877-659-5518, ...
Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Rating …
WebApr 9, 2024 · Several equities research analysts have recently issued reports on the company. Canaccord Genuity Group decreased their price objective on Travere Therapeutics from $44.00 to $42.00 and set a ... WebMay 5, 2024 · Net product sales for the first quarter of 2024 were $46.4 million, compared to $47.4 million for the same period in 2024. The difference is largely attributable to a … nature of competition definition
Drug prices and trends for THIOLA - DrugPatentWatch
WebApr 11, 2024 · Travere Therapeutics Stock Up 2.6 %. TVTX opened at $21.47 on Monday. The company has a debt-to-equity ratio of 8.76, a quick ratio of 3.37 and a current ratio of 3.42. The company has a market ... WebTHIOLA EC is a prescription medication provided in a delayed-release tablet. It is used in combination with high fluid intake, alkali (low acid), and dietary changes to help prevent the formation of one type (cystine) of kidney stones in certain adult and pediatric patients that weigh at least 44 pounds (20 kg) and who do not respond to these ... WebFeb 20, 2024 · THIOLA EC is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria, who are not responsive to these measures alone. ... Distributed by Travere Therapeutics, Inc., San Diego, CA 92130. marine park radiology pc